Past issues are only available to subscribers. If you are not a member, click here to join.

Issue 6 - Feb. 10, 2017
  • MMRF contributes largest disease-specific cancer genome dataset to NCI’s Genomic Data Commons

    It took the Multiple Myeloma Research Foundation nearly a decade and over $40 million to create what the foundation describes as the largest disease-specific cancer genome dataset in existence.

    The first installment of the dataset is now posted on NCI’s Genomic Data Commons, which places the information in the public domain, making it available to researchers.

  • Conversation with The Cancer Letter

    Giusti: The $40 million multiple myeloma dataset will help predict risk and clinical response

    The world’s biggest genomic database on multiple myeloma is being integrated into NCI’s Genomic Data Commons.

    The data on the second most common blood cancer—with genomic information from about 1,400 patients—was compiled by the Multiple Myeloma Research Foundation through a genome mapping initiative and a $40 million network of clinical trials.

  • Steve Hahn takes over day to day operations at MD Anderson

    Steve Hahn, a radiation oncologist, was named deputy to the president and chief operating officer at MD Anderson Cancer Center.

  • GAO report: FDA underestimated actual cancer risk, clearing 25 versions of morcellators in over 20 years

    The Government Accountability Office Feb. 8 released an analysis of FDA’s failure to detect the health hazards of power morcellation, a once widely used procedure that has been shown to upstage uterine cancers.

  • In Brief

    • International teams win £100 million in Cancer Research UK competition 
    • Horning receives Duane Roth Memorial Award
    • Chang and Moore win Ehrlich-Darmstaedter Prize
    • ESMO to present new award at first annual Immuno-Oncology Congress
    • Jupiter Medical Center to use IBM Watson for Oncology technology
    • Fox Chase, Temple earn accreditation for BMT program
    • Cota, Hackensack integrate patient data into Epic EHR system
    • NCCN creates Quick Guide for patients with Waldenström’s Macroglobulinemia
  • Drugs & Targets

    • FDA approves Opdivo for urothelial carcinoma indication
    • GenomeDx, Astellas work to identify genomic drivers of Xtandi response
Issue 5 - Feb. 3, 2017
  • Soon-Shiong drops “MoonShot” trademark, but MD Anderson suit remains unresolved

    Overnight, cancer pharmaceuticals billionaire Patrick Soon-Shiong stopped using the trademark “MoonShot” to describe his health initiatives, opting instead to use the less grabby, but equally ambitious, name “cancer breakthroughs.”

  • Soon-Shiong’s journey from “Rocket Ship” to “MoonShot”—with lots of confusion

    The MD Anderson complaint against Patrick Soon-Shiong and his business entities, filed Nov. 30, 2016, in the U.S. District Court for the Southern District of Texas, argues that the controversial billionaire’s use of the moonshot trademark created confusion that affected both MD Anderson and the White House initiative headed by then Vice President Joe Biden.

  • Cancer groups: Trump travel ban could “retard scientific progress and adversely affect public health”

    President Donald Trump’s recent executive order that temporarily bars travel from seven Muslim-majority countries to the United States will negatively affect research institutions, public health, and innovation, cancer organizations say.

  • Obituary

    LeMaistre, a pioneer of cancer prevention and former MD Anderson president, dies at 92

     

    Charles Aubrey “Mickey” LeMaistre, a former president of MD Anderson Cancer and a pioneer of cancer prevention, died Jan. 27. He was 92.

  • In Brief

    • Keith Flaherty named editor-in-chief of AACR journal Clinical Cancer Research
    • Gottschalk named chair of bone marrow transplantation, cellular therapy at St. Jude
    • Guttridge named associate director for basic research at Ohio State
    • Heath named associate director for translational sciences at Karmanos
    • Howell joins Fox Chase Department of Radiation Oncology
    • NCCN establishes second policy and advocacy fellowship
  • Drugs & Targets

    • MD Anderson, Guardant form partnership to make liquid biopsy standard of care
    • Indivumed to provide tissue samples to Regeneron
    • Addario institute and Scancell form partnership focused on vaccine
    • Perthera enters collaboration with Novartis to identify patients for clinical trials
    • Benitec, Nant Capital initiate head and neck cancer programs
    • GenomeDx joins Astellas in genomic profiling collaboration
  • Funding Opportunities

    SU2C to fund Dream Teams focused on “cancer interception” in pancreas and lungs

    Stand Up To Cancer broke new ground today when the American Association for Cancer Research, its scientific partner, announced to the cancer research community funding to support new Dream Teams focused on “cancer interception” of the pancreas and lungs.

Issue 4 - Jan. 27, 2017
  • How a “cool” trial in rare cancers was born

    About a year ago, Sandip Patel, a young doctor who had just joined the faculty at University of California San Diego Moores Cancer Center, stopped by to see his mentor, Razelle Kurzrock, chair of the SWOG Early Therapeutics and Rare Cancers Committee.

  • MD Anderson posts $169 million loss for first four months of fiscal 2017

    MD Anderson Cancer Center lost $58 million during the month of December 2016.

    This latest operating loss brings total losses $169.4 million for the first four months of fiscal 2017, which began on Sept. 1, 2016.

  • In Brief

    • Miami Cancer Institute Opens, joins MSKCC Alliance
    • LUNGevity, CancerCare launch helpline
    • White paper shows challenges, progress in immunotherapy
    • Study finds undisclosed conflicts in Twitter posts by oncologists
  • Drugs & Targets

    • FDA approves first drug for marginal zone lymphoma
    • Merck, Domain Therapeutics collaborate in immune-oncology